Skip to content

Research for Associated Genes for Gastric Cancer in Family Member With Affected First-Degree Relatives

Research for Associated Genes for Developing Gastric Cancer in Family Member With First-Degree Relatives of Gastric Cancer

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03486574
Enrollment
105
Registered
2018-04-03
Start date
2016-12-07
Completion date
2022-12-31
Last updated
2023-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer, Genetic Predisposition

Brief summary

Familial gastric cancer accounts for 10% of all cases, but predisposing genetic variations is unknown except for CDH1 mutation. Because Germline mutation is believed to be a key aspect of cancer predisposition, we plan to recruit persons with 2 or more affected family members in three-generation pedigree. The investigators will perform a whole-exome sequencing using DNA from blood samples of families including gastric cancer patients and non-gastric cancer patients

Detailed description

1\> Patient selection Enroll criteria: 1\) Gastric cancer patients and their first-degree relatives and 2) family with two or more gastric cancer patients within three-generation pedigree. A three-generation pedigree will be used for diagnostic consideration or risk assessment of rare variation. Personal history will be acquired by questionnaire which asks smoking, alcohol intake, dietary preference, socioeconomic information and history of previous eradication of HP. For any family member with gastric cancer, age at diagnosis, histology type, methods of treatment or pathological reports will be evaluated. 2\> Whole exome sequencing, variant annotation, filtering and prioritization After whole exome sequencing, functional annotation of genetic variants will be conducted using ANNOVAR. 3\> Linkage analyses To perform variant and gene-based linkage analysis in pedigrees, data will be analyzed using pedigree-VAAST. 4\> Validation using a genechip

Interventions

DIAGNOSTIC_TESTPositive result from pathological test

Presence/absence of gastric cancer will be evaluated by upper gastroendoscopy or results of pathological test

Sponsors

Seoul National University Bundang Hospital
Lead SponsorOTHER

Study design

Observational model
FAMILY_BASED
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

: * Gastric cancer patients and their first-degree relatives * Members in family with two or more gastric cancer patients within three- generation pedigree

Exclusion criteria

: * Those who reject the enrollment

Design outcomes

Primary

MeasureTime frameDescription
Genes with logarithm of odds (LOD)>2 in linkage analysis0 day (baseline)Based on LOD at baseline, candidate genes will be selected.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026